| 9例自身免疫性疾病合并获得性血友病A的回顾性临床分析 |
| |
| 引用本文： | 高飞,田淼,李光,杜明珠,周智辉,宋艳萍,董昌虎. 9例自身免疫性疾病合并获得性血友病A的回顾性临床分析[J]. 中华全科医学, 2022, 20(10): 1678-1681. DOI: 10.16766/j.cnki.issn.1674-4152.002677 |
| |
| 作者姓名： | 高飞 田淼 李光 杜明珠 周智辉 宋艳萍 董昌虎 |
| |
| 作者单位： | 1.陕西中医药大学第二临床医学院，陕西 咸阳 712046 |
| |
| 基金项目： | 陕西省自然科学基础研究计划项目2019JM-607陕西省教育厅专项科研计划项目20JK0604 |
| |
| 摘 要： | 目的 分析并总结自身免疫性疾病合并获得性血友病A患者的临床特征、实验室检查结果、治疗方案及疗效，提高对疾病的认识。方法 选择西安市中心医院2012年1月—2020年12月收治的9例自身免疫性疾病合并获得性血友病A的患者，回顾性分析其临床特征、实验室检查结果、治疗方案及疗效。结果 9例患者中，男性4例，女性5例，中位年龄为60.0(42.0～72.5)岁。出血症状存在异质性，以皮肤出血为主，也可出现消化道出血及黄体出血等重要脏器出血。关于清除抑制物的治疗，糖皮质激素单药应用4例(44.5%),环磷酰胺联合泼尼松(CP)方案1例(11.1%),利妥昔单抗联合CP方案或环磷酰胺、长春新碱与泼尼松(COP)方案3例(33.3%),环磷酰胺单药应用1例(11.1%)。其中完全缓解3例(33.3%),部分缓解4例(44.5%),未缓解2例(22.2%),总有效率为77.8%。结论 自身免疫性疾病合并获得性血友病A,起病急，出血较重且存在异质性。采用免疫抑制疗法有效率较高，部分病例在免疫抑制治疗的基础上联合应用利妥昔单抗也可取得较好的疗效。经免疫抑制及补充凝血因子治疗可控制病情，疗效较好，但44.5...
|
| 关 键 词： | 获得性血友病A 回顾性分析 免疫抑制剂 糖皮质激素 利妥昔单抗 |
| 收稿时间： | 2022-02-10 |
A retrospective clinical study of 9 cases with autoimmune diseases combined acquired hemophilia A |
| |
| Affiliation: | The Second Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, China |
| |
| Abstract: | Objective To analyze and summarize the clinical features, laboratory examination results, treatment plan and curative effects of patients with autoimmune diseases combined with acquired hemophilia A, so as to improve the understanding of the disease. Methods Nine patients with autoimmune diseases combined acquired hemophilia A who were admitted by Xi ' an Central Hospital from January 2012 to December 2020 were selected, and their clinical features, laboratory examination results, treatment plans and curative effects were retrospectively analyzed. Results Among the 9 patients, 4 were males and 5 were females. The median age was 60.0 (42.0~72.5) years. Bleeding symptoms were heterogeneous, mainly skin bleeding, but also bleeding from important organs such as gastrointestinal bleeding and corpus luteum hemorrhage. In the treatment of elimination of inhibitors, glucocorticoid monotherapy was used in 4 cases (44.5%), cyclophosphamide and prednisone (CP) regimen in 1 case (11.1%), rituximab combined with CP regimen or cyclophosphamide, vincristine and prednisone (COP) regimen in 3 cases (33.3%), and cyclophosphamide monotherapy in 1 case (11.1%). Among them, 3 cases were complete remission (33.3%), 4 cases were partial remission (44.5%), and 2 cases (22.2%) were not remission, and the total effective rate was 77.8%. Conclusion Autoimmune diseases combined acquired hemophilia A have a rapid onset, heavy bleeding and heterogeneity. The use of immunosuppressive therapy is more effective. In some cases, the combination of rituximab on the basis of immunosuppressive therapy can also achieve better results. After immunosuppression and coagulation factor supplementation, the disease can be quickly controlled and the effect is good, but 44.5% of patients only achieved partial remission after one course of treatment, suggesting that to completely remove the inhibitors, systemic treatment is required for the primary disease, and multiple courses of treatment or longer-term immunosuppressive treatment are required. |
| |
| Keywords: | |
|
| 点击此处可从《中华全科医学》浏览原始摘要信息 |
|
点击此处可从《中华全科医学》下载免费的PDF全文 |
|
